LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Baxter International Inc

Suletud

SektorTervishoid

22.3 1.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.59

Max

22.4

Põhinäitajad

By Trading Economics

Sissetulek

-173M

-51M

Müük

25M

2.8B

P/E

Sektori keskmine

86.308

84.243

Dividenditootlus

3.39

Kasumimarginaal

-1.799

Töötajad

38,000

EBITDA

-46M

416M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+1.84% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.39%

2.28%

Järgmine tulemuste avaldamine

12. veebr 2026

Järgmine dividendimakse kuupäev

31. märts 2026

Järgmine aktsia dividendi kuupäev (ex-date)

27. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

-1.7B

10B

Eelmine avamishind

20.71

Eelmine sulgemishind

22.3

Uudiste sentiment

By Acuity

57%

43%

280 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Baxter International Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. veebr 2026, 23:26 UTC

Suurimad hinnamuutused turgudel

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10. veebr 2026, 22:31 UTC

Tulu

Correction to America Movil 4Q Profit Article

10. veebr 2026, 22:22 UTC

Tulu

America Movil 4Q Profit Jumps on Lower Financial Costs

10. veebr 2026, 23:51 UTC

Market Talk
Tulu

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10. veebr 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10. veebr 2026, 23:40 UTC

Market Talk
Tulu

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10. veebr 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10. veebr 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10. veebr 2026, 22:15 UTC

Tulu

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10. veebr 2026, 22:10 UTC

Tulu

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10. veebr 2026, 22:09 UTC

Tulu

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10. veebr 2026, 22:01 UTC

Tulu

Intact Financial 4Q EPS C$5.24 >IFC.T

10. veebr 2026, 21:54 UTC

Tulu

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10. veebr 2026, 21:53 UTC

Tulu

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10. veebr 2026, 21:51 UTC

Tulu

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10. veebr 2026, 21:51 UTC

Tulu

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10. veebr 2026, 21:51 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10. veebr 2026, 21:50 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q EPS 12c >JHX

10. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10. veebr 2026, 21:50 UTC

Tulu

James Hardie Industries 3Q Adj EPS 24c >JHX

10. veebr 2026, 21:49 UTC

Tulu

James Hardie Industries 3Q Sales $1.24B >JHX

10. veebr 2026, 21:49 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10. veebr 2026, 21:48 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10. veebr 2026, 21:47 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Võrdlus sarnastega

Hinnamuutus

Baxter International Inc Prognoos

Hinnasiht

By TipRanks

1.84% tõus

12 kuu keskmine prognoos

Keskmine 22.13 USD  1.84%

Kõrge 30 USD

Madal 15 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Baxter International Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

8 ratings

2

Osta

5

Hoia

1

Müü

Tehniline skoor

By Trading Central

30.475 / 31.345Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

280 / 352 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
help-icon Live chat